Previous 10 | Next 10 |
Cassava Sciences stock realised a >4,000% gain between 2020 - 2021. The Alzheimer's therapy developer's shares collapsed after scientists and physicians (and short sellers of its stock) began to question Cassava's scientific rigour. There are catalysts in play that can move the...
Clinical-stage pharma company Cassava Sciences (NASDAQ:SAVA) has added more than 15% to reach a two-month high on Tuesday against a recent selloff among biotech stocks and Alzheimer’s drug developers in particular. More than 5.0M Cassava (SAVA) shares have changed hands compared to the...
Gainers: TherapeuticsMD (TXMD) +361%. JanOne (JAN) +70%. Houston American Energy (HUSA) +57%. CatchMark Timber Trust (CTT) +44%. Mullen Automotive (MULN) +43%. Gogoro (GGR) +37%. BlackSky Technology (BKSY) +32%. Cassava Sciences (SAVA) +25%. MicroStrategy (MSTR) +24%. NexImmune (NEXI) +23%. L...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips The article covers the best meme stocks to buy that are worth another look Virgin Galactic ( SPCE ): Growing reservation backlog is a testament to the interest of its customers Cassava Sciences ( SAVA ...
Palm Beach, FL – May 24, 2022 – FinancialNewsMedia.com News Commentary – The Global psychedelic drugs market has been steadily rising for the past few years and is projected to continue at a faster pace in years to come. The rising prevalence of mental depre...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Fintel has released its Short Squeeze Leaderboard for the week. BigBear.ai Holdings (NYSE: BBAI ) tops the list with a 97.44 rating. We’re looking into it, and the four other stocks on the list. Sou...
S3 Partners ran an intriguing screen to find the most crowded shorts in the market. In looking at the stocks under attack, the firm said a short can be considered to be "crowded" if there are large amount of dollars at risk on the short side, a large proportion of a stock's float is being sho...
Commenting on the update provided by Cassava Sciences (NASDAQ:SAVA) on its Phase 3 program for Alzheimer’s candidate simufilam on Thursday, H.C. Wainwright says that the clinical-stage biotech is on track to complete its enrollment in early 2023. The program, comprising two late-stage ...
With its 1Q 2022 results, Alzheimer’s drug developer, Cassava Sciences (NASDAQ:SAVA), said on Thursday that the company’s late-stage program for the experimental therapy Simufilam has so far enrolled more than 120 patients. Cassava (SAVA) has designed RETHINK-ALZ Phase 3 trial t...
Cassava Sciences press release (NASDAQ:SAVA): Q1 GAAP EPS of -$0.44 misses by $0.01. At March 31, 2022, cash and cash equivalents were $209.7 million, with no debt. A total of over 120 subjects have now been enrolled in our Phase 3 studies. Studies are being conducted in over 115 clinical tri...
News, Short Squeeze, Breakout and More Instantly...
Cassava Sciences, Inc. (NASDAQ: SAVA) is one of today's top gainers. The company's shares have moved 24.9% on the day to $12.59. Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.6% to $117.99 on volume of 383,510,118 shares Aptevo Therapeutics Inc. (APVO) rose 73.4% to $0.581 on volume of 315,289,581 shares PROSHARES TRUST (SQQQ) rose 8.7% to $8.11 on volume of 173,682,364 sha...
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...